Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $46.49 to $47.70
• 50-Day Range: $42.57 to $49.72
• 52-Week Range: $19.80 to $50.35
• Volume: 1.01 million shs
• Average Volume: 709,120 shs
• Market Capitalization: $2.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.33
• Consensus Rating: Moderate Buy

Agios Pharmaceuticals Stock Analysis - MarketRank™

Agios Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 552nd out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Agios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($4.85) to ($6.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agios Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agios Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Agios Pharmaceuticals has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.26% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently decreased by 16.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agios Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Agios Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.80

Percentage of Shares Shorted

5.26% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently decreased by 16.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.51

News Sentiment

Agios Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Agios Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for AGIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $474,140.00 in company stock.

Percentage Held by Insiders

Only 4.93% of the stock of Agios Pharmaceuticals is held by insiders.

AGIO Stock Analysis - Frequently Asked Questions

How have AGIO shares performed this year?

Agios Pharmaceuticals' stock was trading at $22.27 at the beginning of 2024. Since then, AGIO shares have increased by 109.0% and is now trading at $46.55.
View the best growth stocks for 2024 here.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by $0.09. The company's quarterly revenue was up 28.4% compared to the same quarter last year.

Who are Agios Pharmaceuticals' major shareholders?

Top institutional investors of Agios Pharmaceuticals include Farallon Capital Management LLC (9.96%), Dimensional Fund Advisors LP (3.87%), Armistice Capital LLC (3.66%) and Marshall Wace LLP (2.00%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, James William Burns, Sarah Gheuens, Cecilia Jones, Kaye I Foster-Cheek, Tsveta Milanova and Theodore James Jr Washburn.
View institutional ownership trends.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGIO
• CUSIP: N/A
• CIK: 1439222
• Web: www.agios.com
• Phone: (617) 649-8600
• Fax: N/A
• Employees: 390
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $51.33
• High Stock Price Target: $55.00
• Low Stock Price Target: $46.00
• Potential Upside/Downside: +10.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-352,090,000.00
• Net Margins: -1,165.69%
• Pretax Margin: -1,165.69%
• Return on Equity: -47.05%
• Return on Assets: -40.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.09
• Quick Ratio: 9.71

Sales & Book Value

• Annual Sales: $31.31 million
• Price / Sales: 84.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.51 per share
• Price / Book: 3.21

Miscellaneous

• Outstanding Shares: 56,773,000
• Free Float: 53,974,000
• Market Cap: $2.64 billion
• Optionable: Optionable
• Beta: 0.75